Kurs
0,00%
Likviditet
7,99 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-18 | 07:30 | Bokslutskommuniké 2025 |
2025-10-30 | 07:30 | Kvartalsrapport 2025-Q3 |
2025-08-20 | 07:30 | Kvartalsrapport 2025-Q2 |
2025-05-28 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
2025-05-27 | - | Årsstämma |
2025-05-27 | - | Kvartalsrapport 2025-Q1 |
2025-02-18 | - | Bokslutskommuniké 2024 |
2024-12-13 | - | Extra Bolagsstämma 2024 |
2024-10-30 | - | Kvartalsrapport 2024-Q3 |
2024-08-20 | - | Kvartalsrapport 2024-Q2 |
2024-05-31 | - | Kvartalsrapport 2024-Q1 |
2024-05-24 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
2024-05-23 | - | Årsstämma |
2024-02-23 | - | Bokslutskommuniké 2023 |
2023-10-24 | - | Kvartalsrapport 2023-Q3 |
2023-08-04 | - | Kvartalsrapport 2023-Q2 |
2023-05-26 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
2023-05-25 | - | Årsstämma |
2023-05-05 | - | Kvartalsrapport 2023-Q1 |
2023-02-17 | - | Bokslutskommuniké 2022 |
2023-01-12 | - | Extra Bolagsstämma 2022 |
2022-11-04 | - | Kvartalsrapport 2022-Q3 |
2022-08-05 | - | Kvartalsrapport 2022-Q2 |
2022-05-30 | - | Kvartalsrapport 2022-Q1 |
2022-05-23 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
2022-05-20 | - | Årsstämma |
2022-02-11 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-27 | - | Kvartalsrapport 2021-Q2 |
2021-05-24 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
2021-05-21 | - | Årsstämma |
2021-05-05 | - | Kvartalsrapport 2021-Q1 |
2021-02-12 | - | Bokslutskommuniké 2020 |
2020-11-13 | - | Kvartalsrapport 2020-Q3 |
2020-08-28 | - | Kvartalsrapport 2020-Q2 |
2020-05-14 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
2020-05-13 | - | Årsstämma |
2020-05-05 | - | Kvartalsrapport 2020-Q1 |
2020-02-11 | - | Bokslutskommuniké 2019 |
2019-11-15 | - | Kvartalsrapport 2019-Q3 |
2019-11-08 | - | Extra Bolagsstämma 2019 |
2019-08-30 | - | Kvartalsrapport 2019-Q2 |
2019-05-13 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
2019-05-10 | - | Årsstämma |
2019-04-24 | - | Kvartalsrapport 2019-Q1 |
2019-02-12 | - | Bokslutskommuniké 2018 |
2018-11-16 | - | Kvartalsrapport 2018-Q3 |
2018-08-31 | - | Kvartalsrapport 2018-Q2 |
2018-05-16 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
2018-05-15 | - | Årsstämma |
2018-05-09 | - | Kvartalsrapport 2018-Q1 |
2018-02-13 | - | Bokslutskommuniké 2017 |
2017-11-03 | - | Kvartalsrapport 2017-Q3 |
2017-08-31 | - | Kvartalsrapport 2017-Q2 |
2017-05-12 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
2017-05-11 | - | Årsstämma |
2017-05-11 | - | Kvartalsrapport 2017-Q1 |
2017-02-09 | - | Bokslutskommuniké 2016 |
2016-11-04 | - | Kvartalsrapport 2016-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
SynAct Pharma AB (“SynAct”) today announced that all members of its board and executive management have agreed to a lock-up arrangement for their shares in the company until December 31, 2025. In total, these lock-up agreements correspond to 6.9% percent of the votes and capital in SynAct Pharma.
The lock-up prevents the selling of shares while being a member of the Board and the executive management, including majority holdings in companies owning shares in SynAct, except what is reasonably needed to cover tax payments applicable for Danish holding companies.
“The members of the board and the entire management team reconfirms their commitments to the future development of the company and have no intention of selling their shares now,” said Jeppe Øvlesen, CEO of SynAct Pharma.
For further information about SynAct Pharma AB, please contact: Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: +45 28 44 75 67
Mail: joo@synactpharma.com
About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.